Faron Receives FDA Orphan Drug Designation for Bexmarilimab in Acute Myeloid Leukemia
August 29, 2023 00:00 ET
|
Faron Pharmaceuticals Oy
ODD further strengthens bexmarilimab program by offering clinical development and commercialization benefitsExpected completion of dose escalation, readout of enrichment cohorts, and Phase II...
Faron Pharmaceuticals Notice of Half-Year Financial Results
August 04, 2023 08:00 ET
|
Faron Pharmaceuticals Oy
TURKU, Finland and BOSTON, Aug. 04, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via...
Faron to Participate in Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference
August 02, 2023 08:00 ET
|
Faron Pharmaceuticals Oy
Management to present on Thursday, August 10 at 12:30-12:55 PM Eastern Time at the InterContinental Boston Hotel in Boston, MassachusettsPresentation will highlight recent updated positive Phase I/II...
Faron to Hold Conference Call to Discuss New Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS
July 19, 2023 04:54 ET
|
Faron Pharmaceuticals Oy
TURKU, Finland and BOSTON, July 19, 2023 (GLOBE NEWSWIRE) -- Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via...
Faron Updates Positive Clinical Data from Phase I/II BEXMAB Study of Bexmarilimab in Relapsed/Refractory AML and MDS BEXMAB Study Update
July 19, 2023 03:00 ET
|
Faron Pharmaceuticals Oy
Three of five patients in the 6 mg/kg bexmarilimab + azacitidine doublet cohort achieved objective responses (CR and mCR)Eight of 15 objective responses observed in all three doublet dosing cohortsOne...
Faron Pharmaceuticals Oy: FDA grants Fast Track Designation to Faron for Traumakine®
January 29, 2018 07:01 ET
|
Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd("Faron" or the "Company") FDA grants Fast Track Designation to Faron for Traumakine® Faron's wholly-owned product for Acute Respiratory Distress Syndrome on track...
FDA has approved Faron's Traumakine® IND
January 24, 2018 07:00 ET
|
Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd("Faron" or the "Company") FDA has approved Faron's Traumakine® IND TURKU - FINLAND, 24 January 2018 - Faron Pharmaceuticals Ltd ("Faron") (AIM: FARN), the...
Faron Pharmaceuticals Oy: Study update: Traumakine® Phase II/III INFORAAA trial for Multi-Organ Failure receives recommendation from IDMC
December 19, 2017 07:01 ET
|
Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd("Faron" or the "Company") Study update: Traumakine® Phase II/III INFORAAA trial for Multi-Organ Failure receives recommendation from IDMC First recommendation...
Faron Pharmaceuticals Oy: Recruitment completed in Traumakine INTEREST Trial
December 11, 2017 07:00 ET
|
Faron Pharmaceuticals Oy
Faron Pharmaceuticals Ltd("Faron" or the "Company") Recruitment completed in Traumakine INTEREST Trial The upcoming read-out will collate intact 90 day morbidity/mortality data alongside 28...
Faron Pharmaceuticals Oy: Appointment of Chief Commercial Officer
December 01, 2017 07:00 ET
|
Faron Pharmaceuticals Oy
Faron Pharmaceuticals Oy("Faron" or the "Company") Appointment of Chief Commercial Officer Dr. Juhana Heinonen, previously AstraZeneca's Global Marketing Director, to steer...